Financials (USD)
Sales 2024 * | 239M | Sales 2025 * | 299M | Capitalization | 2.19B |
---|---|---|---|---|---|
Net income 2024 * | 4M | Net income 2025 * | 25M | EV / Sales 2024 * | 9.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.34 x |
P/E ratio 2024 * |
568
x | P/E ratio 2025 * |
93.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-02-28 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 21-01-24 |
Michael Halpin
COO | Chief Operating Officer | 62 | 17-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 15-01-05 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 15-01-05 |
Robert Zerbe
CHM | Chairman | 73 | 06-01-15 |
1st Jan change | Capi. | |
---|---|---|
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-20.24% | 29.48B | |
+57.29% | 25.43B | |
-18.07% | 11.49B | |
-44.02% | 11.3B | |
-15.61% | 11.1B | |
+4.34% | 8.75B | |
-8.42% | 7.99B |